Pub Date : 2017-07-07DOI: 10.4172/2327-5162.1000243
Aiman Abbas Jafri, S. Sharma, K. Luthra, M. Mehndiratta, Nikhil Khurana, U. Singh
Background: In previous studies, Sharma et al. has already isolated an anti-hyperglycemic compound from the fruit pulp of Eugenia jambolana using HPLC and other chromatographic techniques. However, the effect of antihyperglycemic compound (FIIc) on the expression of PPAR gamma, IRS-1 and IRS-2 in high sucrose diet induced type 2 diabetic rats has not been studied so far. Methods: There were exactly 24 Male Wistar rats were taken and fed on High Sucrose Diet (HSD) for the development of type 2 diabetic animal for 30 weeks. Active compound FIIc was given to group C and Pioglitazone to group D at dose of 20 mg/kg of b.w. orally for 30 weeks respectively. Blood was drawn for the estimation of plasma glucose and serum insulin at week o and at week 30 from retro orbital plexus. At the end of the study animal were sacrificed and organs including pancreas and skeletal muscles were isolated and stored at -80°C. Total RNA was isolated by using Trizol method and expression of PPAR gamma, IRS-1 and IRS-2 was quantified and compared among the study groups by Real Time PCR. Results: After treatment with FIIc for 30 weeks we found a significant reduction in post prandial blood glucose levels in group C rats compared to group B. Serum insulin was also reduced in group C rats compared to group B. In skeletal muscles the mRNA expression of PPAR γ and IRS-1 was found to be 2.48 fold and 2.56 fold increased respectively as compared to group B. Similarly the mRNA expression of IRS-2 in pancreas was found to be 2.69 folds increased as compared to group B. Conclusion: FIIc treatment for 30 weeks improves glycemic control and insulin sensitivity by increasing the mRNA expression of PPAR γ, IRS-1 and IRS-2.
{"title":"Regulation of Gene Expression in Downstream Signaling Molecules by Herbal Compound in Insulin Resistant Diabetic Rats","authors":"Aiman Abbas Jafri, S. Sharma, K. Luthra, M. Mehndiratta, Nikhil Khurana, U. Singh","doi":"10.4172/2327-5162.1000243","DOIUrl":"https://doi.org/10.4172/2327-5162.1000243","url":null,"abstract":"Background: In previous studies, Sharma et al. has already isolated an anti-hyperglycemic compound from the fruit pulp of Eugenia jambolana using HPLC and other chromatographic techniques. However, the effect of antihyperglycemic compound (FIIc) on the expression of PPAR gamma, IRS-1 and IRS-2 in high sucrose diet induced type 2 diabetic rats has not been studied so far. \u0000Methods: There were exactly 24 Male Wistar rats were taken and fed on High Sucrose Diet (HSD) for the development of type 2 diabetic animal for 30 weeks. Active compound FIIc was given to group C and Pioglitazone to group D at dose of 20 mg/kg of b.w. orally for 30 weeks respectively. Blood was drawn for the estimation of plasma glucose and serum insulin at week o and at week 30 from retro orbital plexus. At the end of the study animal were sacrificed and organs including pancreas and skeletal muscles were isolated and stored at -80°C. Total RNA was isolated by using Trizol method and expression of PPAR gamma, IRS-1 and IRS-2 was quantified and compared among the study groups by Real Time PCR. \u0000Results: After treatment with FIIc for 30 weeks we found a significant reduction in post prandial blood glucose levels in group C rats compared to group B. Serum insulin was also reduced in group C rats compared to group B. In skeletal muscles the mRNA expression of PPAR γ and IRS-1 was found to be 2.48 fold and 2.56 fold increased respectively as compared to group B. Similarly the mRNA expression of IRS-2 in pancreas was found to be 2.69 folds increased as compared to group B. \u0000Conclusion: FIIc treatment for 30 weeks improves glycemic control and insulin sensitivity by increasing the mRNA expression of PPAR γ, IRS-1 and IRS-2.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":" ","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46568690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-26DOI: 10.4172/2327-5162.1000242
C. Smith
Coherent frequencies can have a biological effect. A homeopathic potency has a pattern of coherent frequencies. Therefore, homeopathy has a mechanism for its biological activity.
相干频率可能具有生物学效应。顺势疗法的效力具有连贯的频率模式。因此，顺势疗法有其生物活性的机制。
{"title":"Proof of Evidence for Homeopathy","authors":"C. Smith","doi":"10.4172/2327-5162.1000242","DOIUrl":"https://doi.org/10.4172/2327-5162.1000242","url":null,"abstract":"Coherent frequencies can have a biological effect. A homeopathic potency has a pattern of coherent frequencies. Therefore, homeopathy has a mechanism for its biological activity.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"2017 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2017-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000242","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43844885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-20DOI: 10.4172/2327-5162.1000240
Oroma Beatrice Nwanodi
Statement of Purpose: Although 75% of breast cancer patients may use integrative medicine, only 11.5% earlystage breast cancer patients believe integrative medicine has anticancer activity. The gap in users of and firm believers in integrative medicine indicates a need to increase awareness of integrative medicine’s applicability to curative cancer treatment. As diet, nutraceuticals, and traditional Chinese medicine are used by up to 82% of cancer patients who use integrative medicine, this paper focuses on nutraceuticals. As female cancer patients are most likely to use integrative medicine, nutraceuticals specific to breast, cervical, endometrial, and ovarian cancer are reviewed. Methods: PubMed searches in September 2016 and January 2017, and accompanying hand searches were performed for English language, free full text articles published from 2012 onwards. Search terms were combinations of the key words: Homeopathy, phytochemicals, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, cancer, prevention, treatment. Curative nutraceutical treatments were taken from these searches. Supplemental hand searches were performed as needed. Findings: Integrative nutraceutical therapies are based on biologic plausibility. Individual nutraceuticals are frequently comprised of numerous phytochemical types, and have multiple mechanisms of action. Agonistantagonist mechanisms are not exclusive to phytoestrogens, complicating which derivative or whole nutraceutical to use. Research on breast and cervical cancer inhibitors has seemingly outpaced that for endometrial and ovarian cancer. Breast cancer inhibitors include terpenes, isoflavones, organosulphurs, organoselenium compounds, and withanolides. Conclusion and Significance: Potential nutraceutical candidates for curative cancer treatment abound. Discerning which constituents, which extraction method, and which delivery method to use for an efficacious treatment is an essential, lengthy process. If nutraceuticals such as limonene and Kahalalide F move forward to Phase III trials a nutraceutical cancer treatment pipeline may be established. Withaferin-A and derivatives for breast and ovarian cancer appear to be the leading gynecologic cancer nutraceutical drug candidates.
{"title":"Nutraceuticals: Curative Integrative Cancer Treatment","authors":"Oroma Beatrice Nwanodi","doi":"10.4172/2327-5162.1000240","DOIUrl":"https://doi.org/10.4172/2327-5162.1000240","url":null,"abstract":"Statement of Purpose: Although 75% of breast cancer patients may use integrative medicine, only 11.5% earlystage breast cancer patients believe integrative medicine has anticancer activity. The gap in users of and firm believers in integrative medicine indicates a need to increase awareness of integrative medicine’s applicability to curative cancer treatment. As diet, nutraceuticals, and traditional Chinese medicine are used by up to 82% of cancer patients who use integrative medicine, this paper focuses on nutraceuticals. As female cancer patients are most likely to use integrative medicine, nutraceuticals specific to breast, cervical, endometrial, and ovarian cancer are reviewed. Methods: PubMed searches in September 2016 and January 2017, and accompanying hand searches were performed for English language, free full text articles published from 2012 onwards. Search terms were combinations of the key words: Homeopathy, phytochemicals, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, cancer, prevention, treatment. Curative nutraceutical treatments were taken from these searches. Supplemental hand searches were performed as needed. Findings: Integrative nutraceutical therapies are based on biologic plausibility. Individual nutraceuticals are frequently comprised of numerous phytochemical types, and have multiple mechanisms of action. Agonistantagonist mechanisms are not exclusive to phytoestrogens, complicating which derivative or whole nutraceutical to use. Research on breast and cervical cancer inhibitors has seemingly outpaced that for endometrial and ovarian cancer. Breast cancer inhibitors include terpenes, isoflavones, organosulphurs, organoselenium compounds, and withanolides. Conclusion and Significance: Potential nutraceutical candidates for curative cancer treatment abound. Discerning which constituents, which extraction method, and which delivery method to use for an efficacious treatment is an essential, lengthy process. If nutraceuticals such as limonene and Kahalalide F move forward to Phase III trials a nutraceutical cancer treatment pipeline may be established. Withaferin-A and derivatives for breast and ovarian cancer appear to be the leading gynecologic cancer nutraceutical drug candidates.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"2017 1","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2017-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47971844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-19DOI: 10.4172/2327-5162.1000239
G. Rao
Commentary I participated in the 7th World Ayurveda Conference (WAC) in Kolkata a few weeks ago, at the invitation of Dr. Geetha Krishanan, Secretary WAC-2016. As an outsider, I enjoyed the meetings, the exposition and the opportunity to meet experts in various fields of Traditional Medicine. I was frequently asked during the conference, whether I was a Vaidya or a traditional heath provider or promoter? As I explained to the experts who asked me this question, I feel that it is essential for me to provide some introductory explanations, as to why I am interested in Traditional Indian Medicine. I am the founder and CEO of a professional society; South Asian Society on Atherosclerosis and Thrombosis (SASAT). I have been organizing international conference on Atherosclerosis and Thrombosis for over three decades in India. We have published several books on this subject in India [1-6]. During our conference in 2006 (www.sasat.org/ 7_symp_prog_13.htm). We organized a round table discussion on, “The need for integration of Indian Traditional Medicine for the development of affordable healthcare in India”. Since then, we are working on this idea, so that we can develop a comprehensive seamless Integrated Healthcare for India.
{"title":"Opportunities and Challenges in Ayurveda: Global Perspective","authors":"G. Rao","doi":"10.4172/2327-5162.1000239","DOIUrl":"https://doi.org/10.4172/2327-5162.1000239","url":null,"abstract":"Commentary I participated in the 7th World Ayurveda Conference (WAC) in Kolkata a few weeks ago, at the invitation of Dr. Geetha Krishanan, Secretary WAC-2016. As an outsider, I enjoyed the meetings, the exposition and the opportunity to meet experts in various fields of Traditional Medicine. I was frequently asked during the conference, whether I was a Vaidya or a traditional heath provider or promoter? As I explained to the experts who asked me this question, I feel that it is essential for me to provide some introductory explanations, as to why I am interested in Traditional Indian Medicine. I am the founder and CEO of a professional society; South Asian Society on Atherosclerosis and Thrombosis (SASAT). I have been organizing international conference on Atherosclerosis and Thrombosis for over three decades in India. We have published several books on this subject in India [1-6]. During our conference in 2006 (www.sasat.org/ 7_symp_prog_13.htm). We organized a round table discussion on, “The need for integration of Indian Traditional Medicine for the development of affordable healthcare in India”. Since then, we are working on this idea, so that we can develop a comprehensive seamless Integrated Healthcare for India.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"2017 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000239","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45197213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-05-29DOI: 10.4172/2327-5162-C1-024
S. M. Liew
A phobias and stress are the main mental health problems among the Malaysian population, with global prevalence varying from 8% to 18%. Even so, less than 30% who suffer these disturbances seek treatment. The objective of this study is to evaluate and compare the anxiolytic effects of Aconitum napellus and homeopathic complex Vita-C 15 in the acutely stressed C57BL6 mice by using the fecal corticoid test, open field test (OFT) and c-Fos, NMDAR 2B, NPY 1R and NPY 2R activity through the hippocampus. A double blinded randomized controlled study is conducted at Animal Laboratory of Cyberjaya University College of Medical Sciences (CUCMS). All the animals are acclimatized to constant laboratory conditions for 14 days before starting the experiments. Prior to the experiment, a pilot study is performed to identify the most suitable and ideal potency for the homeopathic remedy of Aconitum napellus. The animals are tested (n=3) per group on the potency of 6C, 30C and 200C. The treatments are carried out over 9 days. 48 male C57BL6 mice (n=6), 4-5 weeks of age are used. They are randomly selected and divided into two groups. Group-1 was the healthy control group of mice which are not exposed to acute stress. Group-2 was the stress group. Comprise of mice expose to acute restraint stress. Prior to restraint stress, the treatments given are Aconitum napellus 30 cH, Homeopathic complex Vita-C 15, Diazepam and placebo. Then the results are evaluated by fecal CORT test and open field test by comparing the anxiolytics between pre-test and post-test. Aconitum napellus 30 cH and Homeopathic complex Vita-C 15 are expected to be more effective and can reduce the occurrence of anxiety in the acutely stressed C57BL6 mice. Thus, research into prevention and supportive therapies is necessary and beneficial for this disorder.
{"title":"Comparison of anxiolytic effects of the homeopathic complex Vita-C 15 in compared with Aconitum Napellus in the acutely stressed C57BL6 mice","authors":"S. M. Liew","doi":"10.4172/2327-5162-C1-024","DOIUrl":"https://doi.org/10.4172/2327-5162-C1-024","url":null,"abstract":"A phobias and stress are the main mental health problems among the Malaysian population, with global prevalence varying from 8% to 18%. Even so, less than 30% who suffer these disturbances seek treatment. The objective of this study is to evaluate and compare the anxiolytic effects of Aconitum napellus and homeopathic complex Vita-C 15 in the acutely stressed C57BL6 mice by using the fecal corticoid test, open field test (OFT) and c-Fos, NMDAR 2B, NPY 1R and NPY 2R activity through the hippocampus. A double blinded randomized controlled study is conducted at Animal Laboratory of Cyberjaya University College of Medical Sciences (CUCMS). All the animals are acclimatized to constant laboratory conditions for 14 days before starting the experiments. Prior to the experiment, a pilot study is performed to identify the most suitable and ideal potency for the homeopathic remedy of Aconitum napellus. The animals are tested (n=3) per group on the potency of 6C, 30C and 200C. The treatments are carried out over 9 days. 48 male C57BL6 mice (n=6), 4-5 weeks of age are used. They are randomly selected and divided into two groups. Group-1 was the healthy control group of mice which are not exposed to acute stress. Group-2 was the stress group. Comprise of mice expose to acute restraint stress. Prior to restraint stress, the treatments given are Aconitum napellus 30 cH, Homeopathic complex Vita-C 15, Diazepam and placebo. Then the results are evaluated by fecal CORT test and open field test by comparing the anxiolytics between pre-test and post-test. Aconitum napellus 30 cH and Homeopathic complex Vita-C 15 are expected to be more effective and can reduce the occurrence of anxiety in the acutely stressed C57BL6 mice. Thus, research into prevention and supportive therapies is necessary and beneficial for this disorder.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70260364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-05-17DOI: 10.4172/2327-5162.1000238
Radosław Kujawski, Justyna Baraniak, M. Ożarowski, M. Kujawska, M. Borowska, M. Kania, J. Bartkowiak-Wieczorek, A. Sobczak, A. Gryszczyńska, K. Manikowska, Joanna Liberska, J. Cichocka, M. Szulc, P. Ruszkowski
Despite the increasing number of studies on the molecular actions of quercetin and curcumin, their anticancer efficacy, safety and molecular aspects of chemopreventive action in the ovarian cancer prophylaxis or treatment and also their potential in the sensitization to cytostatics used in the clinical practice remains still not clearly understood. Based on basic studies we have summarized evidences for inhibitory activities of several often studied plantorigin bio-active compounds (mostly quercetin and curcumin) against ovarian cancer cells proliferation, their mechanisms of action as well as their strong potential to sensitization of ovarian cancer cells to the presence of several platinum-based cytostatics - cisplatin and oxaliplatin. Up to date only several dietary, clinical (cohort and case–control) studies evaluating the association of some flavonoids (mostly nonisoflavones) and its subgroup components consumption and ovarian cancer risk were already performed. According to the researchers, there has been no association between ovarian cancer risk and total nonisoflavone flavonoids intake. There is a still an insufficient amount of data designed to explain the effect of quercetin or curcumin (alone or together) on ovarian cancer development and/or its chemotherapy. Obtained results provide limited support for an association between nonisoflavone flavonoids intake and ovarian cancer risk, therefore there is a need for further and more accurate studies to be confirmed. We are of the opinion that this paper will contribute to a better understanding of the molecular basis for positive interactions between concomitant usage of quercetin or curcumin with above-mentioned cytostatics and other bio-active agents. This work may also contribute to an increase in the number of preclinical studies or other clinical, dietary trials using these or other phenolic / alkaloid, plant-origin constituents in order to investigate efficiency and safety of pharmacotherapy of ovarian cancer patients.
{"title":"Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells-A Mini-review","authors":"Radosław Kujawski, Justyna Baraniak, M. Ożarowski, M. Kujawska, M. Borowska, M. Kania, J. Bartkowiak-Wieczorek, A. Sobczak, A. Gryszczyńska, K. Manikowska, Joanna Liberska, J. Cichocka, M. Szulc, P. Ruszkowski","doi":"10.4172/2327-5162.1000238","DOIUrl":"https://doi.org/10.4172/2327-5162.1000238","url":null,"abstract":"Despite the increasing number of studies on the molecular actions of quercetin and curcumin, their anticancer efficacy, safety and molecular aspects of chemopreventive action in the ovarian cancer prophylaxis or treatment and also their potential in the sensitization to cytostatics used in the clinical practice remains still not clearly understood. \u0000Based on basic studies we have summarized evidences for inhibitory activities of several often studied plantorigin bio-active compounds (mostly quercetin and curcumin) against ovarian cancer cells proliferation, their mechanisms of action as well as their strong potential to sensitization of ovarian cancer cells to the presence of several platinum-based cytostatics - cisplatin and oxaliplatin. Up to date only several dietary, clinical (cohort and case–control) studies evaluating the association of some flavonoids (mostly nonisoflavones) and its subgroup components consumption and ovarian cancer risk were already performed. According to the researchers, there has been no association between ovarian cancer risk and total nonisoflavone flavonoids intake. There is a still an insufficient amount of data designed to explain the effect of quercetin or curcumin (alone or together) on ovarian cancer development and/or its chemotherapy. Obtained results provide limited support for an association between nonisoflavone flavonoids intake and ovarian cancer risk, therefore there is a need for further and more accurate studies to be confirmed. We are of the opinion that this paper will contribute to a better understanding of the molecular basis for positive interactions between concomitant usage of quercetin or curcumin with above-mentioned cytostatics and other bio-active agents. This work may also contribute to an increase in the number of preclinical studies or other clinical, dietary trials using these or other phenolic / alkaloid, plant-origin constituents in order to investigate efficiency and safety of pharmacotherapy of ovarian cancer patients.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"2017 1","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2017-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46319675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-04-07DOI: 10.4172/2327-5162.1000237
Richa Gupta, S. Sharma, U. Singh
Background: Germinated Glycine max seeds have been known to have anti-hyperglycemic effects; however, a comprehensive study pertaining to this has never been experimentally determined. Methods: The aqueous extract of 12 h germinated Glycine max seeds (gGmax) were orally administered to Streptozotocin induced diabetic rats for 28 days and the effects were observed on glycemic index, lipid profile, antioxidant parameters alpha amylase and alpha glucosidase activity. Further the histomorphological changes were seen in the rat’s pancreas. Finally, the metabolite profiling was done. Results: There was a significant improvement in FBG and OGTT in diabetic rats treated with gGmax after a period of 28 days. The extract also led to a substantial increase in the levels of insulin and c-peptide as compared to diabetic control rats with marked improvement in insulin resistance. Lipid profile and atherogenic factors were significantly improved. Histomorphological examination of pancreatic tissue revealed increased number of islets and β-cells in treated rats as compared to diabetic controls. Subsequently, marked suppression in the activity of alphaamylase and alpha- glucosidase was observed. Conclusion: The antidiabetic property of the extract is attributed through the improvement in insulin secretion, suppression of post- prandial hyperglycemia and β-cell regeneration. Besides its antidiabetic properties, Glycine max seeds also demonstrated salutary effects on the management of dyslipidemia which may be mediated through scavenging of free radicals as well as suppression of atherogenic lipid variants and apolipoproteins. Overall this study represents Glycine max seeds as a promising therapeutic agent for diabetes and dyslipidemia.
{"title":"Salutary Effects of Germinated Glycine max Seeds on Post Prandial Hyperglycemia and Dyslipidemia - Evidence from In-vivo and In-vitro Studies","authors":"Richa Gupta, S. Sharma, U. Singh","doi":"10.4172/2327-5162.1000237","DOIUrl":"https://doi.org/10.4172/2327-5162.1000237","url":null,"abstract":"Background: Germinated Glycine max seeds have been known to have anti-hyperglycemic effects; however, a comprehensive study pertaining to this has never been experimentally determined. \u0000Methods: The aqueous extract of 12 h germinated Glycine max seeds (gGmax) were orally administered to Streptozotocin induced diabetic rats for 28 days and the effects were observed on glycemic index, lipid profile, antioxidant parameters alpha amylase and alpha glucosidase activity. Further the histomorphological changes were seen in the rat’s pancreas. Finally, the metabolite profiling was done. \u0000Results: There was a significant improvement in FBG and OGTT in diabetic rats treated with gGmax after a period of 28 days. The extract also led to a substantial increase in the levels of insulin and c-peptide as compared to diabetic control rats with marked improvement in insulin resistance. Lipid profile and atherogenic factors were significantly improved. Histomorphological examination of pancreatic tissue revealed increased number of islets and β-cells in treated rats as compared to diabetic controls. Subsequently, marked suppression in the activity of alphaamylase and alpha- glucosidase was observed. \u0000Conclusion: The antidiabetic property of the extract is attributed through the improvement in insulin secretion, suppression of post- prandial hyperglycemia and β-cell regeneration. Besides its antidiabetic properties, Glycine max seeds also demonstrated salutary effects on the management of dyslipidemia which may be mediated through scavenging of free radicals as well as suppression of atherogenic lipid variants and apolipoproteins. Overall this study represents Glycine max seeds as a promising therapeutic agent for diabetes and dyslipidemia.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":" ","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2017-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000237","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47228437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-31DOI: 10.4172/2327-5162.1000236
Elena Mejías Gil, M. V. G. López-Arza
Objectives: The aim of this study was to review the effects achieved by the Qigong on balance in the last 17 years publications. Design: The performed search included quantitative researches about the effects of Qigong on balance, published between 01/01/2000 and 12/31/2016. There was no language restriction and reviews were not included in the analysis. Databases: PubMed, CSIC, Cochrane Library, Scopus, PEDro, Dialnet, JSTAGE, JTCM. Results: A total of 2966 studies were founded, 11 of them were selected after having applied the established inclusion and exclusion criteria. Conclusion: Currently, there is not enough evidence to conclusively demonstrate the benefits of Qigong in improving balance. However, based on the analyzed studies, we can say that there are signs of an improvement.
{"title":"Systematic Review about the Effects of Qigong Therapeutic Exercise on Balance","authors":"Elena Mejías Gil, M. V. G. López-Arza","doi":"10.4172/2327-5162.1000236","DOIUrl":"https://doi.org/10.4172/2327-5162.1000236","url":null,"abstract":"Objectives: The aim of this study was to review the effects achieved by the Qigong on balance in the last 17 \u0000 years publications. \u0000Design: The performed search included quantitative researches about the effects of Qigong on balance, \u0000 published between 01/01/2000 and 12/31/2016. There was no language restriction and reviews were not included in \u0000 the analysis. \u0000Databases: PubMed, CSIC, Cochrane Library, Scopus, PEDro, Dialnet, JSTAGE, JTCM. \u0000Results: A total of 2966 studies were founded, 11 of them were selected after having applied the established \u0000 inclusion and exclusion criteria. \u0000Conclusion: Currently, there is not enough evidence to conclusively demonstrate the benefits of Qigong in \u0000 improving balance. However, based on the analyzed studies, we can say that there are signs of an improvement.","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"6 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000236","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48002564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-03-27DOI: 10.4172/2327-5162.1000235
Farhana Ijaz, Z. Iqbal, I. Rahman, N. Ali, M. Afzal
{"title":"People-Plants Interaction and Its Uses: A Science of Four Words âÂÂEthnobotanyâÂÂ","authors":"Farhana Ijaz, Z. Iqbal, I. Rahman, N. Ali, M. Afzal","doi":"10.4172/2327-5162.1000235","DOIUrl":"https://doi.org/10.4172/2327-5162.1000235","url":null,"abstract":"","PeriodicalId":90094,"journal":{"name":"Alternative & integrative medicine","volume":"6 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2327-5162.1000235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45356466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：